The bank holiday turned out to be a hot one, not least in the takeover arena. First, Shire Pharmaceutical accepted a £46 billion offer from Takeda of Japan — though the stock market did not seem wholly convinced that the deal will proceed. If it does, should we care?
Shire is a FTSE100 company that began in the UK and ended up stateless.
Already a subscriber? Log in
Easter flash sale:
10 issues for $1
Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.
- Weekly delivery of the magazine
- Unlimited access to spectator.com.au and app
- Spectator Australia podcasts and newsletters
- Full access to spectator.co.uk
Or
Unlock 3 articles a month
You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.
Comments
Easter flash sale: 10 issues for $1
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
CLAIM OFFER 10 issues for $1Already a subscriber? Log in